Capricor Therapeutics, Inc. ( (CAPR) ) has released its Q1 earnings. Here is a breakdown of the information Capricor Therapeutics, Inc. presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, particularly Duchenne muscular dystrophy (DMD). In its latest earnings report, Capricor announced that its Biologics License Application for deramiocel, a treatment for DMD, is under priority review by the FDA, with a target decision date set for August 31, 2025. The company also highlighted the planned initiation of a Phase 1 clinical trial for its StealthX™ exosome vaccine in collaboration with the National Institute of Allergy and Infectious Diseases. Financially, Capricor reported a net loss of $24.4 million for the first quarter of 2025, with no revenue generated in the period, compared to $4.9 million in the same quarter last year. Despite the loss, the company maintains a strong cash position of approximately $145 million, expected to support operations into 2027. Looking ahead, Capricor remains optimistic about its strategic initiatives and regulatory milestones, positioning itself for potential growth and development in the rare disease therapeutic market.